Zepbound Vision Changes: What the Label and Studies Report
Zepbound vision changes are on the label for people with type 2 diabetes. The Zepbound FDA label says diabetic retinopathy, an eye disease of diabetes, can get worse for a time when blood sugar improves fast. NAION, an optic nerve condition, is not on the Zepbound label. The EU warning about NAION covers semaglutide only.
Studies on tirzepatide and the eyes point in different directions. Most were in people with type 2 diabetes. This page shows which finding applies to which drug.
Short answer
- What the label warns about
- Diabetic retinopathy can get worse for a time when blood sugar improves fast. The label says people with a history of it should be monitored.
- Blurred vision
- The Zepbound label lists blurred vision as one sign of low blood sugar.
- NAION and Zepbound
- Not on the Zepbound, Mounjaro, Ozempic or Wegovy US labels. The June 2025 EU safety committee statement covers semaglutide only.
- What to do
- The label says to tell your healthcare provider if you have changes in vision during treatment.
Sources: Zepbound FDA label; EMA PRAC, June 2025
What the Zepbound label says about vision changes
The label's eye warning is about diabetic retinopathy. This is damage to the back of the eye from diabetes. The label says it has briefly worsened in some people when blood sugar improved fast. People with a history of it should be monitored.
The patient information says it in plain words. It lists changes in vision in people with type 2 diabetes. It says to tell your healthcare provider if your vision changes while on Zepbound.
Mounjaro is the same drug. Its label tells doctors to ask patients to report any change in vision. The EU product information for Mounjaro has the same retinopathy warning. It says people with diabetic retinopathy should be watched closely.
For how the two brands relate, see is Zepbound the same as Mounjaro.
Sources: Zepbound FDA label; Mounjaro FDA label; EMA Mounjaro product information
Blurred vision as a sign of low blood sugar
The Zepbound label lists blurred vision as a sign of low blood sugar. The other signs it names are dizziness or light-headedness, sweating, confusion or drowsiness, and headache.
So blurred vision on Zepbound is not always an eye problem. The label gives it as one sign of low blood sugar.
Sources: Zepbound FDA label
What studies found on tirzepatide and diabetic retinopathy
Two recent studies in type 2 diabetes point in different directions. One found less retinopathy on tirzepatide than on other GLP-1 drugs. The other found more new severe retinopathy, mostly in people who already had some.
- A 2026 study in Ophthalmology Retina compared tirzepatide with other GLP-1 drugs. Tirzepatide had a lower risk of retinopathy (hazard ratio 0.79) and macular edema (0.82). It also had a lower risk of eye bleeds or retinal detachment (0.66), and of eye procedures to save vision (0.65).
- A 2025 study in Diabetologia found higher odds of new proliferative (severe) retinopathy on tirzepatide. This was mostly in people who already had retinopathy.
For comparison, the Ozempic label reports retinopathy problems in 3.0% on Ozempic and 1.8% on placebo. The Zepbound label warning is aimed at people with a history of diabetic retinopathy.
Sources: Ophthalmol Retina 2026 cohort; Diabetologia 2025 cohort; Ozempic FDA label
NAION and Zepbound: what applies and what does not
NAION is not on the Zepbound label. Our full-text search of the US labels for Zepbound, Mounjaro, Ozempic and Wegovy found no listing for it.
NAION stands for non-arteritic anterior ischemic optic neuropathy. It is an optic nerve condition. In June 2025, the safety committee of the European Medicines Agency (PRAC) made a call on semaglutide. It said semaglutide product information should list NAION as a very rare side effect. Very rare means it may affect up to 1 in 10,000 people. That statement is about semaglutide. It does not cover tirzepatide.
The study evidence on tirzepatide is mixed:
- A 2025 JAMA Network Open study in type 2 diabetes pooled semaglutide and tirzepatide. NAION came up in 35 people (0.04%) on the drugs. It came up in 19 people (0.02%) in a matched group (hazard ratio 1.76).
- The 2026 Ophthalmology Retina study found less NAION on tirzepatide than on other GLP-1 drugs (hazard ratio 0.45).
- A 2025 JAMA Ophthalmology case series looked at eye problems on these drugs. It said it could not tell if the drugs caused them.
For GLP-1 drugs as a group, a 2026 Diabetes Care meta-analysis found a higher NAION risk (odds ratio 1.70). Still, the actual risk was small. It was 0.09% in the GLP-1 group, a difference of 0.037%. That is about 1 extra case for every 2,700 people treated.
A Danish and Norwegian study looked at semaglutide in type 2 diabetes. It found a higher NAION risk than with SGLT-2 inhibitors. It said the actual risk remains low. For how semaglutide and tirzepatide compare overall, see tirzepatide vs semaglutide.
Sources: EMA PRAC, June 2025; JAMA Netw Open 2025; Ophthalmol Retina 2026 cohort; JAMA Ophthalmol 2025 case series; Diabetes Care 2026 meta-analysis; Diabetes Obes Metab 2025, Danish-Norwegian cohort
Which eye finding covers which drug
Many eye headlines are about semaglutide, or pool both drugs. The table shows what each source covers.
| Finding | Source | Drug covered | Who |
|---|---|---|---|
| Retinopathy can briefly worsen with fast glucose improvement | Zepbound FDA label, EMA Mounjaro information | Tirzepatide | People with diabetic retinopathy |
| Tell a provider about vision changes | Zepbound, Mounjaro and Wegovy FDA labels | Tirzepatide and semaglutide | People with type 2 diabetes (Zepbound, Wegovy wording) |
| NAION added as a very rare side effect | EMA safety committee, June 2025 | Semaglutide only | Semaglutide users |
| NAION 0.04% vs 0.02% | JAMA Netw Open 2025 | Semaglutide or tirzepatide, pooled | Type 2 diabetes |
| Lower NAION and retinopathy risk than other GLP-1 drugs | Ophthalmol Retina 2026 | Tirzepatide vs other GLP-1 drugs | Type 2 diabetes |
| Higher odds of new proliferative retinopathy | Diabetologia 2025 | Tirzepatide | Type 2 diabetes, mainly with existing retinopathy |
None of these is a randomised trial of tirzepatide and NAION. The studies are cohort studies or a case series.
Sources: Zepbound FDA label; Mounjaro FDA label; Wegovy FDA label; EMA PRAC, June 2025; EMA Mounjaro product information; JAMA Netw Open 2025; Ophthalmol Retina 2026 cohort; Diabetologia 2025 cohort
Does blurry vision from tirzepatide go away?
No label or trial says how often blurred vision on tirzepatide goes away. The Zepbound label calls the retinopathy worsening it describes temporary.
The labels and studies here do not say if vision loss from a GLP-1 drug can be reversed. That question belongs with an eye doctor.
Sources: Zepbound FDA label
When to tell a healthcare provider
The Zepbound label says to tell your healthcare provider if you have changes in vision during treatment.
For semaglutide, the European Medicines Agency gives one rule. Anyone with sudden loss of vision, or eyesight that gets worse fast, should contact their doctor without delay.
For the dose steps, see the tirzepatide dosage guide. For the full side effect picture, see our GLP-1 side effects guide.
Sources: Zepbound FDA label; EMA PRAC, June 2025
Zepbound vision questions
Can tirzepatide affect your eyesight?+
It can in some people with type 2 diabetes. The Zepbound label says diabetic retinopathy can briefly get worse when blood sugar improves fast. It tells people with type 2 diabetes to report changes in vision. It also lists blurred vision as a sign of low blood sugar.
Does blurry vision from tirzepatide go away?+
No label or trial says how often it goes away. The Zepbound label calls the retinopathy worsening it describes temporary. It lists blurred vision as one sign of low blood sugar. The label says to tell your healthcare provider about any change in vision.
Does blurred vision from semaglutide go away?+
No source here says how often it goes away. The Wegovy label tells people with type 2 diabetes to report changes in vision. For sudden vision loss on semaglutide, the European Medicines Agency says to contact a doctor without delay.
What are the rare side effects of Zepbound?+
For the eyes, the Zepbound label warns about diabetic retinopathy in people with type 2 diabetes. It can briefly get worse when blood sugar improves fast. NAION, an optic nerve condition, is not on the Zepbound label.
Can vision loss from GLP-1 be reversed?+
The labels and studies here do not say. The European Medicines Agency says anyone on semaglutide with sudden vision loss should contact their doctor without delay.
Does Zepbound cause NAION?+
It is not on the Zepbound label. The EU NAION statement covers semaglutide only. A 2025 study pooled semaglutide and tirzepatide. It found NAION in 0.04%, against 0.02% in a matched group. A 2026 study found less NAION on tirzepatide than on other GLP-1 drugs. No study here tests tirzepatide alone against no drug.
Sources: Zepbound FDA label; Wegovy FDA label; EMA PRAC, June 2025; JAMA Netw Open 2025; Ophthalmol Retina 2026 cohort
Related tirzepatide guides
This guide is for educational purposes only and is not medical advice. It describes what FDA labels, European Medicines Agency documents and published studies report about vision and tirzepatide. Questions about your own eyes or medicine belong with a licensed clinician.